

Attorney Docket No. 00487.00011

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:)	BOX PCT
)	
Karim MALIK, et al.)	National Phase Application
)	PCT/GB00/02741
Serial No. Unassigned)	Filed: July 17, 2000
)	
Filed: Concurrently Herewith)	Group Art Unit: Unassigned
)	
For: DIAGNOSTIC METHOD)	Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted for consideration by the United States Patent and Trademark Office in accordance with the duty of disclosure.

Transmitted herewith is:

- ☒ [X] A PTO 1449 form
- ☐ [] A Background Art Information Paper
- ☒ [X] A copy of each item of information listed on the PTO 1449 form
- ☐ [] Concise explanation of non-English language information
 - ☐ [] concise explanation of relevance:
 - ☐ [] English translation of foreign language information
 - ☒ [X] English language version of foreign patent office report citing information
 - ☐ [] English language abstract(s) of foreign patent document(s)

- ☐ This application relies, under 35 U.S.C. §120, on the earlier filing date of U.S. Application Serial No. ****, filed ***. The information identified on the attached PTO 1449 form was submitted to and/or cited by the Patent and Trademark Office in this earlier application and, therefore, copies are not required to be provided in this application.

1. ☒ This Information Disclosure Statement is filed before the later of:
- ☐ three months from the filing date of this national application;
 - ☒ three months from the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or
 - ☐ the mailing date of a first office action on the merits.

In accordance with 37 CFR 1.97(b), no fee is required.

2. ☐ This Information Disclosure Statement is filed after the events noted in paragraph 1, but before either:
- ☐ a final action under 37 CFR 1.113, or an action that otherwise closes prosecution,
 - ☐ a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(c), also enclosed is

- ☐ a fee under 37 CFR 1.17(p) for \$180.00; or
- ☐ a certification as stated below.

3. ☐ This Information Disclosure Statement is filed before payment of the issue fee, but after either
- ☐ a final action under 37 CFR 1.113, or an action that otherwise closes prosecution;
 - ☐ a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(d), also enclosed is:

- ☐ a certification, as stated below; and
- ☐ the IDS processing fee set forth in 37 CFR 1.17(p)(1) in the amount of \$180.00.

Certification

The undersigned states:

☐ Each item of Information contained in this Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or

☐ No item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.

TOTAL FEES: \$

☐ A check for the amount of the above indicated TOTAL FEES is attached.

☐ Please charge Deposit Account No. 19-0733 in the amount of \$.

☐ A check for \$ is enclosed.

☒ No fee is required.


☐ Please charge or credit Deposit Account No. 19-0733 for an deficiency or overpayment associated with this Information Disclosure Statement.

A duplicate copy of this sheet is enclosed for accounting purposes.

It is respectfully requested that the Examiner fully consider each item of information, initial the enclosed Form PTO-1449 in the appropriate place to indicate that the information has been considered, and return a copy of the initialed form to the undersigned in accordance with MPEP Section 609.

Respectfully submitted,

BANNER & WITCOFF, LTD.

By: 
Sarah A. Kagan
Registration No. 32,141

Eleventh Floor
1001 G Street, N.W.
Washington, D.C. 20001-4597
(202) 508-9100

Dated: January 15, 2002

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION Sheet 1 of 2		Attorney Docket No. 00487.00011		International Serial No. PCT/GB00/02741		
		Applicant(s): Karim MALIK, et al.				
		International Filing Date: July 17, 2000		Group: Unassigned		
U.S. PATENT DOCUMENTS						
Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	5,350,840	09/27/94	Call, et al.			
FOREIGN PATENT DOCUMENTS						
Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation
	99/01580	01/14/99	WIPO			<div style="display: flex; justify-content: space-between;"> YES NO </div>
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)						
	Malik, K.T.A., et al.: "Identification of an antisense WT1 promoter in intron 1: implications for WT1 gene regulation", ONCOGENE, GB, BASINGSTOKE, HANTS, vol. 11, 1995, pp.1589-1595, XP002910386					
	HILTUNEN, M.Q., et al.: "Hypermethylation of the WT1 and calcitonin gene promoter regions at chromosome 11p in Human colorectal cancer", BRITISH JOURNAL OF CANCER, vol. 76, no. 9, 1997, pp. 1124-1130, XP000979772					
	LAUX, D., et al.: "Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 238, 1997, p. A1195, XP000979879					
	HUANG T H-M, et al.: "Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique" CANCER RESEARCH, vol. 57, 1997, pp. 1030-1034, XP002161163					
	FEINBERG, A.P.: "Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction", CANCER RESEARCH, vol. 59, 1999, pp. 1743s-1746s, XP002161164					
	TYCKO B: "DNA methylation in genomic imprinting" MUTATION RESEARCH, NL, AMSTERDAM, vol. 386, no. 2, 1997, pp. 131-140, XP002070305					
	MOULTON, T., et al.: "Genomic imprinting and Wilms' tumor", MEDICAL AND PEDIATRIC ONCOLOGY, vol. 27, 1996, pp. 476-483, XP000979774					
	MOORWOOD, K., et al.: "Definition of a novel negative regulatory element of the WT1 antisense promoter", ANTICANCER RESEARCH, vol. 18, no. 6C, 1998, pp. 4909-4910, XP000979768					
	MOORWOOD, K., et al.: Antisense WT1 transcription parallels sense mRNA and protein expression in fetal kidney and can elevate protein levels in vitro", JOURNAL OF PATHOLOGY, vol. 185, 1998, pp. 352-359, XP000981275					
	GESSLER, M. and BURNS, G.A.P.: "Sequence of the WT1 upstream region including the Wit-1 gene", GENOMICS, vol. 17, 1993, pp. 499-501, XP000981270					
EXAMINER				DATE CONSIDERED		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>						
<small>**Copies of references not provided at the time of this submission.</small>						

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION Sheet 2 of 2		Attorney Docket No. 00487.00011		International Serial No. PCT/GB00/02741	
		Applicant(s): Karim MALIK, et al.			
		International Filing Date: July 17, 2000		Group: Unassigned	

U.S. PATENT DOCUMENTS						
Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS							
Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)	
	CAMPBELL, C.E., et al.: "Antisense transcripts and protein binding motifs within the Wilms tumour (WT1) locus" ONCOGENE, vol. 9, 1994, pp. 583-595, XP000981271
	MALIK, K., et al.: "Identification and differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor", CANCER RESEARCH, vol. 60, 2000, pp. 2356-2360, XP002161165

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

** Copies of references not provided at the time of this submission.